Search

Your search keyword '"HANS KRAGTEN"' showing total 6 results
Start Over Author "HANS KRAGTEN" Topic cardiology and cardiovascular medicine
6 results on '"HANS KRAGTEN"'

1. Diabetes and treatment of chronic heart failure in a large real‐world heart failure population

Author

Stefan Koudstaal, Gerard C.M. Linssen, Jesse F. Veenis, Hans Kragten, Nadea Y Y Al-Windy, Luc W. Eurlings, Sumant P Radhoe, Jasper J. Brugts, Hans-Peter Brunner-La Rocca, Chris van der Lee, Aukje van der Spank, Cardiology, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), and RS: Carim - H02 Cardiomyopathy

Subjects
Male, medicine.medical_specialty, Population, Prohormone, Renal function, Heart failure, DIAGNOSIS, Ventricular Function, Left, EJECTION FRACTION, MILD PATIENTS HOSPITALIZATION, MELLITUS, Mineralocorticoid receptor, Diabetes mellitus, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Humans, Diseases of the circulatory (Cardiovascular) system, ESC GUIDELINES, education, Aged, Mineralocorticoid Receptor Antagonists, RISK, education.field_of_study, Ejection fraction, business.industry, BETA-BLOCKERS, Guideline adherence, Stroke Volume, Original Articles, medicine.disease, EFFICACY, DYSFUNCTION, Drug class, RC666-701, EPLERENONE, Original Article, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

Aims: Although diabetes mellitus (DM) is a common co-morbidity in chronic heart failure (HF) patients, European data on concurrent HF and DM treatment are lacking. Therefore, we have studied the HF treatment of patients with and without DM. Additionally, with the recent breakthrough of sodium–glucose cotransporter 2 (SGLT2) inhibitors in the field of HF, we studied the potential impact of this new drug in a large cohort of HF patients. Methods and results: A total of 7488 patients with chronic HF with a left ventricular ejection fraction 2, P Conclusions: In this large real-world HF registry, a high prevalence of DM was observed and diabetics more often received guideline-recommended target doses. Based on current evidence, the majority of patients would fulfil the enrichment criteria of SGLT2 trials in HF and the impact of this new drug class will be large.

Published
2022

2. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: The results of the AFFIRM-AHF study

Author

Marco Metra, Marcus Andreas Ohlsson, Basil S. Lewis, Wolfram Doehner, Peter van der Meer, Irakli Khintibidze, Hans Kragten, Bridget-Anne Kirwan, Jose C. Nicolau, Vincent Fabien, Tim Friede, Nicolas Danchin, Ewa A. Jankowska, Gerasimos Filippatos, Alain Cohen-Solal, Fabio Dorigotti, Hadi Skouri, Davor Miličić, Andre Keren, Alexander Parkhomenko, Jarosław Drożdż, David Sim, Stuart J. Pocock, Michael Motro, Javed Butler, Domingo A. Pascual-Figal, Theresa McDonagh, Henry J. Dargie, Josep Comín-Colet, Maria Dorobantu, Mikhail Kosiborod, Frank Ruschitzka, Stephan von Haehling, Piotr Ponikowski, Stefan D. Anker, Felipe Martinez, Cardiovascular Centre (CVC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), leboeuf, Christophe, Wrocław Medical University, Socar Research S.A. [Nyon, Switzerland] (SR), London School of Hygiene and Tropical Medicine (LSHTM), Saint Luke's Mid America Heart Institute, University of Missouri [Kansas City] (UMKC), University of Missouri System, University of Mississippi Medical Center (UMMC), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], King‘s College London, Universitatea din Bucuresti (UB), Medical University of Łódź (MUL), National and Kapodistrian University of Athens (NKUA), Université d'Athènes (UOA), Assuta Hospital in Ramat HaHayal [Tel Aviv-Yafo, Israel] (AHRH), Tbilisi State University, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], Prague University of Economics and Business, Università degli Studi di Brescia = University of Brescia (UniBs), Civic Hospital of Brescia, University of Zagreb, Skane University Hospital [Malmo], Lund University [Lund], National Scientific Center 'M.D. Strazhesko Institute of Cardiology' [Kyiv, Ukraine] (NSC/MDSIC), Universidad de Murcia, University hospital of Zurich [Zurich], National Heart Centre Singapore (NHCS), American University of Beirut Faculty of Medicine and Medical Center (AUB), University Medical Center Groningen [Groningen] (UMCG), Rappaport faculty of Medicine, Technion - Israel Institute of Technology [Haifa], L’Hospitalet de Llobregat [Barcelona, Spain], Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL), University Medical Center Göttingen (UMG), German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), University of Glasgow, Tel Aviv University (TAU), Kfar Saba and Sackler School of Medicine, Vifor Pharma Ltd [Glattbrugg, Switzerland], and University College of London [London] (UCL)

Subjects
medicine.medical_specialty, Randomization, Heart diseases, Iron, Health-related quality of life, Population, Heart failure, 030204 cardiovascular system & hematology, Placebo, law.invention, Malalties del cor, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Quality of life, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, law, Clinical Research, Internal medicine, medicine, Humans, Clinical Trials, AcademicSubjects/MED00200, 030212 general & internal medicine, education, education.field_of_study, Ejection fraction, Dèficit de ferro, Anemia, Iron-Deficiency, business.industry, Iron deficiency, Acute heart failure, medicine.disease, Confidence interval, 3. Good health, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Dietary Supplements, Intravenous ferric carboxymaltose therapy, Iron deficiency diseases, Randomized clinical trial, Cardiology and Cardiovascular Medicine, business
Abstract

Aims Patients with heart failure (HF) and iron deficiency experience poor health-related quality of life (HRQoL). We evaluated the impact of intravenous (IV) ferric carboxymaltose (FCM) vs. placebo on HRQoL for the AFFIRM-AHF population. Methods and results The baseline 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which was completed for 1058 (535 and 523) patients in the FCM and placebo groups, respectively, was administered prior to randomization and at Weeks 2, 4, 6, 12, 24, 36, and 52. The baseline KCCQ-12 overall summary score (OSS) mean ± standard error was 38.7 ± 0.9 (FCM group) and 37.1 ± 0.8 (placebo group); corresponding values for the clinical summary score (CSS) were 40.9 ± 0.9 and 40.1 ± 0.9. At Week 2, changes in OSS and CSS were similar for FCM and placebo. From Week 4 to Week 24, patients assigned to FCM had significantly greater improvements in OSS and CSS scores vs. placebo [adjusted mean difference (95% confidence interval, CI) at Week 4: 2.9 (0.5–5.3, P = 0.018) for OSS and 2.8 (0.3–5.3, P = 0.029) for CSS; adjusted mean difference (95% CI) at Week 24: 3.0 (0.3–5.6, P = 0.028) for OSS and 2.9 (0.2–5.6, P = 0.035) for CSS]. At Week 52, the treatment effect had attenuated but remained in favour of FCM. Conclusion In iron-deficient patients with HF and left ventricular ejection fraction, Graphical Abstract

Published
2021

3. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure

Author

Davor Miličić, Peter van der Meer, Bridget Anne Kirwan, Piotr Ponikowski, Jarosław Drożdż, David Sim, Irakli Khintibidze, Marcus Andreas Ohlsson, Hadi Skouri, Frank Ruschitzka, Felipe Martinez, Andre Keren, Maria Dorobantu, Stefan D. Anker, Alexander Parhomenko, Marco Metra, Vincent Fabien, Jose C. Nicolau, Teba Haboubi, Ewa A. Jankowska, Gerasimos Filippatos, Domingo A. Pascual-Figal, Theresa McDonagh, Hans Kragten, Cardiovascular Centre (CVC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), University of Zurich, and Ponikowski, Piotr

Subjects
Male, Placebo-controlled study, Recurrent heart failure hospitalizations, 030204 cardiovascular system & hematology, Ferric Compounds, THERAPY, DISEASE, 0302 clinical medicine, Quality of life, RISK, OUTCOMES, Ejection fraction, Anemia, Iron-Deficiency, DEATH, Iron deficiency, Middle Aged, PREVALENCE, Hospitalization, Survival Rate, Treatment Outcome, Injections, Intravenous, 10209 Clinic for Cardiology, Female, Cardiology and Cardiovascular Medicine, Switzerland, medicine.medical_specialty, Cardiovascular mortality, Anemia, 610 Medicine & health, Acute heart failure, Ferric carboxymaltose, Placebo, DIAGNOSIS, 2705 Cardiology and Cardiovascular Medicine, 03 medical and health sciences, Double-Blind Method, Internal medicine, medicine, Humans, ANEMIA, Maltose, Aged, Retrospective Studies, Heart Failure, Inpatients, Dose-Response Relationship, Drug, Transferrin saturation, business.industry, medicine.disease, Heart failure, REGISTRY, Quality of Life, business, Follow-Up Studies
Abstract

Aims: Iron deficiency (ID) is a common co-morbidity in heart failure (HF), associated with impaired functional capacity, poor quality of life and increased morbidity and mortality. Treatment with intravenous (i.v.) ferric carboxymaltose (FCM) has shown improvements in functional capacity, symptoms and quality of life in stable HF patients with reduced ejection fraction. The effect of i.v. iron supplementation on morbidity and mortality in patients hospitalised for acute HF (AHF) and who have ID has yet to be established. The objective of the present article is to present the rationale and design of the AFFIRM-AHF trial (ClinicalTrials.gov NCT02937454) which will investigate the effect of i.v. FCM (vs. placebo) on recurrent HF hospitalisations and cardiovascular (CV) mortality in iron-deficient patients hospitalised for AHF. Methods: AFFIRM-AHF is a multicentre, randomised (1:1), double-blind, placebo-controlled trial which recruited 1100 patients hospitalised for AHF and who had iron deficiency ID defined as serum ferritin

Published
2019

4. Agatston score of the descending aorta is independently associated with coronary events in a low-risk population

Author

Hans Kragten, Luuk I.B. Heckman, Frederique E C M Peeters, Elton A. M. P. Dudink, Harry J.G.M. Crijns, Justin G.L.M. Luermans, Rutger J. Haest, Joachim E. Wildberger, Bas L.J.H. Kietselaer, Bob Weijs, Sibel Altintas, Cardiologie, RS: CARIM - R2.01 - Clinical atrial fibrillation, Promovendi CD, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), MUMC+: MA Med Staf Artsass Cardiologie (9), MUMC+: MA Alg Ond Onderz Cardiologie (9), RS: CARIM - R2.08 - Electro mechanics, RS: CARIM - R3.11 - Imaging, MUMC+: MA Med Staf Spec Cardiologie (9), MUMC+: DA Beeldvorming (5), Beeldvorming, and MUMC+: MA Cardiologie (9)

Subjects
medicine.medical_specialty, Acute coronary syndrome, Heart disease, ARTERY CALCIUM, PREDICTION, X-ray computed, HEART-DISEASE, 030204 cardiovascular system & hematology, tomography, Coronary artery disease, 03 medical and health sciences, 0302 clinical medicine, medicine.artery, Internal medicine, Ascending aorta, medicine, COMPUTED-TOMOGRAPHY, 030212 general & internal medicine, ALL-CAUSE MORTALITY, Aorta, Framingham Risk Score, business.industry, physiologic, CARDIOVASCULAR RISK, medicine.disease, PREVENTION, Cardiac Risk Factors and Prevention, follow-up studies, CALCIFICATION, aorta, ATHEROSCLEROSIS, Descending aorta, Cardiology, cardiovascular system, Cardiology and Cardiovascular Medicine, Agatston score, business, coronary artery disease
Abstract

ObjectivesA standard coronary artery calcium scan includes part of the aorta. This additional information is often not included in routine analyses. We aimed to determine the feasibility of assessing the Agatston score of the descending aorta calcification (DAC) on standard coronary calcium scans and the association of this score with coronary events in a low-risk study population.MethodsBetween January 2008 and March 2011, 390 consecutive patients who were referred for cardiac CT as part of work-up for pulmonary vein isolation (n=115) or assessment of presence of coronary artery disease (n=275) were included. At baseline, all patients were free of a history of cardiovascular disease. Two independent observers determined the Agatston score of the ascending aorta and descending aorta.ResultsA total of 16 patients (4.1%) developed coronary events (acute coronary syndrome (n=6) and symptomatic significant coronary artery disease requiring treatment (n=10)) during a follow-up of 67±12 months, with more events in patients with calcifications in the descending aorta than in those without (8.4% vs 3.7 %; p=0.08). Multivariable Cox regression, corrected for Framingham Risk Score (FRS) and coronary Agatston score (CAC), revealed that DAC was independently associated with coronary events (per 100 units; HR: 1.06, 95% CI 1.02 to 1.09; p=0.001). DAC furthermore increased the identification of patients that will experience a coronary event (area under the curve: 0.68 for FRS only, 0.75 for FRS+CAC and 0.78 for FRS+CAC+DAC).ConclusionsThe Agatston score of the descending aorta could be included in the standard analysis of cardiac CT scans of low-risk patients since it holds valuable information for the prediction of coronary events.

Published
2018

5. INSERTION OF A MINIATURIZED INSERTABLE CARDIAC MONITOR OUTSIDE THE TRADITIONAL HOSPITAL SETTING: RESULTS FROM THE RIO 2 INTERNATIONAL STUDY

Author

Kurt Stromberg, John D. Rogers, Hans Kragten, Angel Moya, Rishi Anand, Christopher Piorkowski, Prashanthan Sanders, Robert C. Kowal, and M. Rizwan Sohail

Subjects
medicine.medical_specialty, Hospital setting, business.industry, medicine, Medical emergency, Cardiology and Cardiovascular Medicine, medicine.disease, business, Intensive care medicine
Published
2017

6. IMPROVEMENT OF RISK FACTOR CONTROL AFTER AN ACUTE CORONARY SYNDROME BY A NURSE COORDINATED PREVENTION PROGRAM: RESULTS FROM A RANDOMIZED TRIAL

Author

Jan Tijssen, A.J. Withagen, Paul A.R. de Milliano, Ron J.G. Peters, Harald T. Jørstad, Clemens von Birgelen, Hans Kragten, Marco Alings, Keesjan de Vries, Dirk J. Lok, Jan-Melle van Dantzig, Wybren Jaarsma, and Anho Liem

Subjects
medicine.medical_specialty, Acute coronary syndrome, Randomized controlled trial, law, business.industry, medicine, Risk factor, Intensive care medicine, business, medicine.disease, Cardiology and Cardiovascular Medicine, law.invention
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results